{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:51:34Z","timestamp":1768463494854,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T00:00:00Z","timestamp":1236038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s10620-009-0744-1","type":"journal-article","created":{"date-parts":[[2009,3,2]],"date-time":"2009-03-02T19:17:45Z","timestamp":1236021465000},"page":"476-483","source":"Crossref","is-referenced-by-count":11,"title":["Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid"],"prefix":"10.1007","volume":"55","author":[{"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayant A.","family":"Talwalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea A.","family":"Gossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill C.","family":"Keach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice L.","family":"Petz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta A.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,3]]},"reference":[{"key":"744_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","volume":"362","author":"JA Talwalkar","year":"2003","unstructured":"Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53\u201361. doi: 10.1016\/S0140-6736(03)13808-1 .","journal-title":"Lancet"},{"key":"744_CR2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1572-0241.2000.01857.x","volume":"95","author":"PM Huet","year":"2000","unstructured":"Huet PM, Deslauriers J, Tran A, et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol. 2000;95:760\u2013767. doi: 10.1111\/j.1572-0241.2000.01857.x .","journal-title":"Am J Gastroenterol"},{"key":"744_CR3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548\u20131554.","journal-title":"N Engl J Med"},{"key":"744_CR4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","volume":"106","author":"KD Lindor","year":"1994","unstructured":"Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284\u20131290.","journal-title":"Gastroenterology"},{"key":"744_CR5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"EJ Heathcote","year":"1994","unstructured":"Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149\u20131156.","journal-title":"Hepatology"},{"key":"744_CR6","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759\u2013766.","journal-title":"Hepatology"},{"key":"744_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","volume":"39","author":"RE Poupon","year":"2003","unstructured":"Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12\u201316. doi: 10.1016\/S0168-8278(03)00192-2 .","journal-title":"J Hepatol"},{"key":"744_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","volume":"72","author":"KD Lindor","year":"1997","unstructured":"Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137\u20131140.","journal-title":"Mayo Clin Proc"},{"key":"744_CR9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"A Pares","year":"2000","unstructured":"Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32:561\u2013566. doi: 10.1016\/S0168-8278(00)80216-0 .","journal-title":"J Hepatol"},{"key":"744_CR10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884\u2013890. doi: 10.1016\/S0016-5085(97)70183-5 .","journal-title":"Gastroenterology"},{"key":"744_CR11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115\u2013121. doi: 10.1111\/j.1478-3231.1999.tb00020.x .","journal-title":"Liver"},{"key":"744_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715\u2013720. doi: 10.1053\/j.gastro.2005.12.029 .","journal-title":"Gastroenterology"},{"key":"744_CR13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871\u2013877. doi: 10.1002\/hep.22428 .","journal-title":"Hepatology"},{"key":"744_CR14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1089\/ars.2005.7.1346","volume":"7","author":"R Bataller","year":"2005","unstructured":"Bataller R, Sancho-Bru P, Gines P, et al. Liver fibrogenesis: a new role for the renin\u2013angiotensin system. Antioxid Redox Signal. 2005;7:1346\u20131355. doi: 10.1089\/ars.2005.7.1346 .","journal-title":"Antioxid Redox Signal"},{"key":"744_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/CS20070026","volume":"113","author":"FJ Warner","year":"2007","unstructured":"Warner FJ, Lubel JS, McCaughan GW, et al. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007;113:109\u2013118. doi: 10.1042\/CS20070026 .","journal-title":"Clin Sci (Lond)"},{"key":"744_CR16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","volume":"10","author":"M Ruiz-Ortega","year":"2001","unstructured":"Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321\u2013329. doi: 10.1097\/00041552-200105000-00005 .","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"744_CR17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20665","volume":"41","author":"R Bataller","year":"2005","unstructured":"Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology. 2005;41:1046\u20131055. doi: 10.1002\/hep.20665 .","journal-title":"Hepatology"},{"key":"744_CR18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/gast.2001.25480","volume":"121","author":"JR Jonsson","year":"2001","unstructured":"Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148\u2013155. doi: 10.1053\/gast.2001.25480 .","journal-title":"Gastroenterology"},{"key":"744_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1386-6346(01)00102-4","volume":"21","author":"T Ohishi","year":"2001","unstructured":"Ohishi T, Saito H, Tsusaka K, et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res. 2001;21:147\u2013158. doi: 10.1016\/S1386-6346(01)00102-4 .","journal-title":"Hepatol Res"},{"key":"744_CR20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/jhep.2001.28231","volume":"34","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745\u2013750.","journal-title":"Hepatology"},{"key":"744_CR21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(01)00146-5","volume":"35","author":"G Paizis","year":"2001","unstructured":"Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol. 2001;35:376\u2013385. doi: 10.1016\/S0168-8278(01)00146-5 .","journal-title":"J Hepatol"},{"key":"744_CR22","first-page":"1499","volume":"49","author":"LN Ramalho","year":"2002","unstructured":"Ramalho LN, Ramalho FS, Zucoloto S. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology. 2002;49:1499\u20131502.","journal-title":"Hepatogastroenterology"},{"key":"744_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00129784-200303050-00006","volume":"3","author":"A Pines","year":"2003","unstructured":"Pines A, Fisman EZ. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs. 2003;3:351\u2013360. doi: 10.2165\/00129784-200303050-00006 .","journal-title":"Am J Cardiovasc Drugs"},{"key":"744_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","volume":"10","author":"ER Dickson","year":"1989","unstructured":"Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1\u20137. doi: 10.1002\/hep.1840100102 .","journal-title":"Hepatology"},{"key":"744_CR25","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18:S79\u2013S83.","journal-title":"Clin Infect Dis"},{"key":"744_CR26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","volume":"45","author":"ZM Younossi","year":"1999","unstructured":"Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295\u2013300.","journal-title":"Gut"},{"key":"744_CR27","volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","author":"J Ware","year":"1994","unstructured":"Ware J, Kosinski M, Keller S. SF-36 physical and mental health summary scales: a user\u2019s manual. Boston: The Health Institute; 1994."},{"key":"744_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103\u2013112. doi: 10.1007\/BF00432479 .","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"744_CR29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/1381612033455396","volume":"9","author":"A Molteni","year":"2003","unstructured":"Molteni A, Ward WF, Ts\u2019ao CH, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des. 2003;9:751\u2013761. doi: 10.2174\/1381612033455396 .","journal-title":"Curr Pharm Des"},{"key":"744_CR30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","volume":"40","author":"S Yokohama","year":"2004","unstructured":"Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222\u20131225. doi: 10.1002\/hep.20420 .","journal-title":"Hepatology"},{"key":"744_CR31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3748\/wjg.v12.i2.322","volume":"12","author":"S Yokohama","year":"2006","unstructured":"Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12:322\u2013326.","journal-title":"World J Gastroenterol"},{"key":"744_CR32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32679","volume":"36","author":"Y Terui","year":"2002","unstructured":"Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002;36:1022. doi: 10.1053\/jhep.2002.32679 .","journal-title":"Hepatology"},{"key":"744_CR33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00535-004-1523-6","volume":"40","author":"H Yoshiji","year":"2005","unstructured":"Yoshiji H, Noguchi R, Fukui H. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol. 2005;40:215\u2013216. doi: 10.1007\/s00535-004-1523-6 .","journal-title":"J Gastroenterol"},{"key":"744_CR34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.1840100516","volume":"10","author":"PM Grambsch","year":"1989","unstructured":"Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 1989;10:846\u2013850. doi: 10.1002\/hep.1840100516 .","journal-title":"Hepatology"},{"key":"744_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","volume":"17","author":"MI Prince","year":"2003","unstructured":"Prince MI, Mitchison HC, Ashley D, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther. 2003;17:137\u2013143. doi: 10.1046\/j.1365-2036.2003.01398.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR36","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/hep.20698","volume":"41","author":"JJ Theal","year":"2005","unstructured":"Theal JJ, Toosi MN, Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology. 2005;41:1305\u20131312. doi: 10.1002\/hep.20698 .","journal-title":"Hepatology"},{"key":"744_CR37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-4-13","volume":"4","author":"PC Borg ter","year":"2004","unstructured":"ter Borg PC, van Os E, van den Broek WW, et al. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial. BMC Gastroenterol. 2004;4:13. doi: 10.1186\/1471-230X-4-13 . ISRCTN88246634.","journal-title":"BMC Gastroenterol"},{"key":"744_CR38","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","volume":"51","author":"JA Talwalkar","year":"2006","unstructured":"Talwalkar JA, Donlinger JJ, Gossard AA, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci. 2006;51:1985\u20131991. doi: 10.1007\/s10620-006-9397-5 .","journal-title":"Dig Dis Sci"},{"key":"744_CR39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0168-8278(00)80385-2","volume":"32","author":"MI Prince","year":"2000","unstructured":"Prince MI, James OF, Holland NP, et al. Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol. 2000;32:368\u2013373. doi: 10.1016\/S0168-8278(00)80385-2 .","journal-title":"J Hepatol"},{"key":"744_CR40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1572-0241.2000.01774.x","volume":"95","author":"ZM Younossi","year":"2000","unstructured":"Younossi ZM, Kiwi ML, Boparai N, et al. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol. 2000;95:497\u2013502. doi: 10.1111\/j.1572-0241.2000.01774.x .","journal-title":"Am J Gastroenterol"},{"key":"744_CR41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1542-3565(03)00323-9","volume":"2","author":"A Rannard","year":"2004","unstructured":"Rannard A, Buck D, Jones DE, et al. Assessing quality of life in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2004;2:164\u2013174. doi: 10.1016\/S1542-3565(03)00323-9 .","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR42","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/j.1572-0241.2001.03956.x","volume":"96","author":"ZM Younossi","year":"2001","unstructured":"Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96:2199\u20132205. doi: 10.1111\/j.1572-0241.2001.03956.x .","journal-title":"Am J Gastroenterol"},{"key":"744_CR43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/0091270004267194","volume":"44","author":"SG Chrysant","year":"2004","unstructured":"Chrysant SG, Chrysant GS. Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004;44:827\u2013836. doi: 10.1177\/0091270004267194 .","journal-title":"J Clin Pharmacol"},{"key":"744_CR44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1527-3466.1995.tb00304.x","volume":"13","author":"M Stimpel","year":"1995","unstructured":"Stimpel M, Bonn R, Koch B, et al. Pharmacology and clinical use of the new ACE inhibitor moexipril. Cardiovasc Drug Rev. 1995;13:211\u2013229. doi: 10.1111\/j.1527-3466.1995.tb00304.x .","journal-title":"Cardiovasc Drug Rev"},{"key":"744_CR45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1378\/chest.126.2.400","volume":"126","author":"D Sondhi","year":"2004","unstructured":"Sondhi D, Lippman M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large teaching hospital. Chest. 2004;126:400\u2013404. doi: 10.1378\/chest.126.2.400 .","journal-title":"Chest"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0744-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-009-0744-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0744-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:42:47Z","timestamp":1559245367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-009-0744-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s10620-009-0744-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,3]]}}}